美国食品和药物管理局批准了Evrysdi的片型,为脊柱肌肉缩提供了更简单的治疗方法. FDA approves tablet form of Evrysdi, offering easier treatment for Spinal Muscular Atrophy.

林业发展局核准了一种用于治疗作为婴儿死亡遗传原因的脊椎肌肉萎缩症(SMA)的Evrysdi平板药。 The FDA has approved a tablet form of Evrysdi for treating Spinal Muscular Atrophy (SMA), a genetic cause of infant death. 这套新药片是SMA的首次非侵入性治疗,简化了日常管理,增加了病人获得治疗的机会。 This new tablet, the first non-invasive treatment for SMA, simplifies daily administration and increases accessibility for patients. Evrysdi增加了对运动神经元健康至关重要的SMN蛋白质的生产。 Evrysdi increases the production of the SMN protein, which is crucial for motor neuron health. 这项核准是在一项研究之后作出的,该项研究显示,平板药的有效性和安全性与现有的口头解决办法相似。 This approval follows a study showing the tablet's effectiveness and safety are comparable to the existing oral solution.